Frank G. Scholl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Frank G. Scholl has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Steven Bibevski
The Heart Institute, Joe DiMaggio Children's Hospital
2 shared publications - Brittany A. Gonzalez
Department of Biomedical Engineering, Florida International University, Miami, FL 33174, USA
1 shared publication Carole Krohn
Society of Thoracic Surgeons; 633 N. Saint Clair Street; Chicago, Illinois; USA
1 shared publicationCastigliano M. Bhamidipati
Department of Surgery, Oregon Health and Science University, Portland, Oregon, USA
1 shared publicationDonna McDonald
Society of Thoracic Surgeons; 633 N. Saint Clair Street; Chicago, Illinois; USA
1 shared publication- Elena Ladich
Memorial HealthCare System, Joe DiMaggio Children’s Hospital, Hollywood, FL 33021, USA
1 shared publication
Latest Publications
- Open Access
- 13 November 2025
- Published by Elsevier in JTCVS Techniques
- Vol. 36, 102152
Half-turned truncal switch for transposition of the great arteries with left ventricular outflow tract obstruction
- 13 November 2025
- Published by Elsevier in JTCVS Techniques
- Vol. 36, 102152
Open AccessHalf-turned truncal switch for transposition of the great arteries with left ventricular outflow tract obstruction
- 1 December 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 114 (6) , 2338-2345
Anomalous Aortic Origin of Right Coronary Artery: Outcomes of Surgical and Nonsurgical Treatment
- 1 December 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 114 (6) , 2338-2345
Anomalous Aortic Origin of Right Coronary Artery: Outcomes of Surgical and Nonsurgical Treatment
- 10 December 2021
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 114 (6) , 2323-2329
Assessment of Current Society of Thoracic Surgeons Data Elements for Adults With Congenital Heart Disease
- 10 December 2021
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 114 (6) , 2323-2329
Assessment of Current Society of Thoracic Surgeons Data Elements for Adults With Congenital Heart Disease
- Open Access
- 16 July 2021
- Published by MDPI AG in Bioengineering
- Vol. 8 (7) , 100
De Novo Valve Tissue Morphology Following Bioscaffold Mitral Valve Replacement in a Juvenile Non-Human Primate Model
The utility of implanting a bioscaffold mitral valve consisting of porcine small intestinal submucosa (PSIS) in a juvenile baboon model (12 to 14 months old at the time of implant; n = 3) to assess their in vivo tissue remodeling responses was investigated. Our findings demonstrated that the PSIS mitral valve exhibited the robust presence of de novo extracellular matrix (ECM) at all explantation time points (at 3-, 11-, and 20-months). Apart from a significantly lower level of proteoglycans in the implanted valve’s annulus region (p < 0.05) at 3 months compared to the 11- and 20-month explants, there were no other significant differences (p > 0.05) found between any of the other principal valve ECM components (collagen and elastin) at the leaflet, annulus, or chordae tendinea locations, across these time points. In particular, neochordae tissue had formed, which seamlessly integrated with the native papillary muscles. However, additional processing will be required to trigger accelerated, uniform and complete valve ECM formation in the recipient. Regardless of the specific processing done to the bioscaffold valve, in this proof-of-concept study, we estimate that a 3-month window following bioscaffold valve replacement is the timeline in which complete regeneration of the valve and integration with the host needs to occur.
- 16 July 2021
- Published by MDPI AG in Bioengineering
- Vol. 8 (7) , 100
Open AccessDe Novo Valve Tissue Morphology Following Bioscaffold Mitral Valve Replacement in a Juvenile Non-Human Primate Model
The utility of implanting a bioscaffold mitral valve consisting of porcine small intestinal submucosa (PSIS) in a juvenile baboon model (12 to 14 months old at the time of implant; n = 3) to assess their in vivo tissue remodeling responses was investigated. Our findings demonstrated that the PSIS mitral valve exhibited the robust presence of de novo extracellular matrix (ECM) at all explantation time points (at 3-, 11-, and 20-months). Apart from a significantly lower level of proteoglycans in the implanted valve’s annulus region (p < 0.05) at 3 months compared to the 11- and 20-month explants, there were no other significant differences (p > 0.05) found between any of the other principal valve ECM components (collagen and elastin) at the leaflet, annulus, or chordae tendinea locations, across these time points. In particular, neochordae tissue had formed, which seamlessly integrated with the native papillary muscles. However, additional processing will be required to trigger accelerated, uniform and complete valve ECM formation in the recipient. Regardless of the specific processing done to the bioscaffold valve, in this proof-of-concept study, we estimate that a 3-month window following bioscaffold valve replacement is the timeline in which complete regeneration of the valve and integration with the host needs to occur.
- 1 April 2010
- Published by SAGE Publications in World Journal for Pediatric and Congenital Heart Surgery
- Vol. 1 (1) , 132-136
Preliminary Experience With Cardiac Reconstruction Using Decellularized Porcine Extracellular Matrix Scaffold: Human Applications in Congenital Heart Disease
An ideal material for repair of congenitally malformed hearts would encourage tissue regeneration with growth potential. Decellularized porcine small intestinal submucosa extracellular matrix (SIS-ECM) promotes tissue regeneration in animal models and noncardiac human applications. This retrospective review evaluates SIS-ECM for reconstruction of congenital heart defects. From June 2007 to May 2009, SIS-ECM patches were used in 43 operations on 40 patients aged 2 days to 13 years. In 16 cases, the SIS-ECM was used for pericardial closure. The SIS-ECM was used for cardiac or great vessel repair in 37 cases: atrial septal defect repair in 11, pulmonary arterioplasty in 10, right ventricular outflow tract patch in 6, pulmonary monocusp valve creation in 5, superior vena cava patch in 2 and aortoplasty in 2, valve leaflet augmentation in 2, and repair of unroofed coronary sinus in 1. Follow-up was complete. There were 5 deaths, all unrelated to the SIS-ECM. Mean follow-up was 7.85 months (0.5-24 months). No pericardial effusions or intracardiac or intravascular thromboses occurred related to the SIS-ECM. The patches did not shrink or calcify. Four of 5 monocusp valves were competent and none were stenotic. One patient who underwent tricuspid valve anterior leaflet augmentation with SIS-ECM required tricuspid valve replacement 4 months later for severe regurgitation following a catheter-based procedure. Explanted tissue showed resorption of the SIS-ECM, replacement with organized collagen, and re-endothelialization. Repair of congenital heart defects using SIS-ECM is feasible and safe. In valve reconstruction, this procedure shows potential for replacement by autologous tissue. Longer-term follow-up is required to assess the potential for growth.
- 1 April 2010
- Published by SAGE Publications in World Journal for Pediatric and Congenital Heart Surgery
- Vol. 1 (1) , 132-136
Preliminary Experience With Cardiac Reconstruction Using Decellularized Porcine Extracellular Matrix Scaffold: Human Applications in Congenital Heart Disease
An ideal material for repair of congenitally malformed hearts would encourage tissue regeneration with growth potential. Decellularized porcine small intestinal submucosa extracellular matrix (SIS-ECM) promotes tissue regeneration in animal models and noncardiac human applications. This retrospective review evaluates SIS-ECM for reconstruction of congenital heart defects. From June 2007 to May 2009, SIS-ECM patches were used in 43 operations on 40 patients aged 2 days to 13 years. In 16 cases, the SIS-ECM was used for pericardial closure. The SIS-ECM was used for cardiac or great vessel repair in 37 cases: atrial septal defect repair in 11, pulmonary arterioplasty in 10, right ventricular outflow tract patch in 6, pulmonary monocusp valve creation in 5, superior vena cava patch in 2 and aortoplasty in 2, valve leaflet augmentation in 2, and repair of unroofed coronary sinus in 1. Follow-up was complete. There were 5 deaths, all unrelated to the SIS-ECM. Mean follow-up was 7.85 months (0.5-24 months). No pericardial effusions or intracardiac or intravascular thromboses occurred related to the SIS-ECM. The patches did not shrink or calcify. Four of 5 monocusp valves were competent and none were stenotic. One patient who underwent tricuspid valve anterior leaflet augmentation with SIS-ECM required tricuspid valve replacement 4 months later for severe regurgitation following a catheter-based procedure. Explanted tissue showed resorption of the SIS-ECM, replacement with organized collagen, and re-endothelialization. Repair of congenital heart defects using SIS-ECM is feasible and safe. In valve reconstruction, this procedure shows potential for replacement by autologous tissue. Longer-term follow-up is required to assess the potential for growth.